drugset / Trial / NCT02287415

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

NCT02287415

Phase 1 Completed 13 enrolled Bial - Portela C S.A.
NaSingle-groupOpen-labelTreatment

Summary

Multiple-dose, open-label, single-period study consisting of three consecutive phases

Timeline

Start
2002-05
Primary completion
2002-07
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown
Subject Warfarin Small molecule

Indications